General Information of Drug (ID: DM8AZQ3)

Drug Name
difluoroagomelatine Drug Info
Synonyms difluoroagomelatine; GTPL7776; CHEMBL1946221
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
57381112
TTD Drug ID
DM8AZQ3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Melatonin DMKWFBT Depression 6A70-6A7Z Approved [3]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [4]
Tasimelteon DMLOQ1V Insomnia 7A00-7A0Z Approved [5]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [6]
LY-156735 DM5IX9M Anxiety disorder 6B00-6B0Z Phase 2 [7]
Agomelatine DMXYA5K Major depressive disorder 6A70.3 Withdrawn from market [8]
Luzindole DMXRJQV Sleep-wake disorder 7A00-7B2Z Terminated [9]
S-20928 DMQDWMJ Sleep-wake disorder 7A00-7B2Z Terminated [10]
GR-133347 DMNRJA0 Anxiety disorder 6B00-6B0Z Terminated [11]
GR-131663 DMKAGLV Anxiety disorder 6B00-6B0Z Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melatonin receptor type 1A (MTNR1A) TT0WAIE MTR1A_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7776).
2 Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem. 2012 Mar;49:310-23.
3 The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
4 MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
7 Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
8 Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
9 Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
10 Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
11 US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
12 Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.